L A M Y

LMMY: 15-12G · delisting

Exousia Bio, Inc. (formerly L A M Y) filed a Form 15-12G on August 31, 2026 to terminate registration of its $0.001 par value common stock under Section 12(g) of the Securities Exchange Act of 1934. The company checked both Rule 12g-4(a)(1) and Rule 12h-3(b)(1)(i) and reported approximately 9 holders of record as of the certification date, far below the thresholds that require public company reporting. The filing was signed by Chief Executive Officer Matthew Dwyer. As a result, Exousia Bio will cease filing periodic reports with the SEC and its common stock will effectively lose over-the-counter quotes, leaving any remaining holders without public financial disclosure.

SEC 15-12G•1mo ago

LMMY: 10-Q · periodic report

Exousia Bio, Inc. reported zero revenue and a net loss of $50,897 for the nine months ended February 28, 2026. The company disclosed that it has no cash on hand and a working capital deficit of $261,023, leading management to raise substantial doubt about its ability to continue as a going concern. In November 2025, the company completed the acquisition of Exousia AI, a clinical-stage biotechnology firm, and subsequently changed its name from LAMY to Exousia Bio. Following the acquisition, the company entered into a rescission agreement in March 2026 to cancel 21,000,000 shares previously issued to Progenicyte Japan CO., LTD. Liquidity remains a critical issue as the company cannot satisfy its maturing obligations. A $250,000 convertible promissory note issued to GBII Partners Inc. matured on March 26, 2026, and remains unpaid, which may result in significant dilution if converted at default prices.

SEC 10-Q•4mo ago